Abstract
Background: As is well-known, serotonin-reuptake inhibitors (SRIs) are unsuccessful in management of forty to sixty percent of patients suffering from obsessivecompulsive disorder (OCD). So, purpose of the present trial was to assess that whether addon aripiprazole, as adjunctive to SRIs, is helpful in cases with treatment-resistant OCD.
Method: In an Open-prospective, single-arm interventional study with blinded rating, sixteen patients with OCD, who had not improved noticeably by serotonin-reuptake inhibitors, after maximum dosage and period, were allocated to get aripiprazole plus their SRIs for eight weeks. Management outcome was measured by means of the Yale-Brown Obsessive Compulsive Scale (YBOCS). Complete reaction to the abovementioned augmentative therapy was demarcated of at least fifty percent reduction in YBOCS’ score and partial reaction as equivalent to or >25% - <50% reduction in YBOCS in comparison with the starting point.
Results: Neither of patients responded with at least 25% decrease in YBOCS score to the aripiprazole addition (20 mg/day). 18% of cases experienced a reduction between 10-20%, and 68% of them less than 10%. Two patients did not show any change at all. The mean+/-SD baseline YBOCS’ score of 35.2 +/- 2.9 dropped to a mean of 32.8 +/- 4.1 at endpoint with a mean reduction of 8.8+/- 7.8% (p<0.06).
Conclusion: Within the limits of statistical power, this assessment does not offer additional proof that adding of aripiprazole to current SRI treatment could be worthwhile for cases suffering from treatment-resistant OCD.
Keywords: Antipsychotic, aripiprazole, obsessive-compulsive disorder, treatment resistant.
Current Psychopharmacology
Title:Aripiprazole Addition to Serotonin Reuptake Inhibitor in Treatment-Resistant Obsessive-Compulsive Disorder
Volume: 3
Author(s): Saeed Shoja Shafti
Affiliation:
Keywords: Antipsychotic, aripiprazole, obsessive-compulsive disorder, treatment resistant.
Abstract: Background: As is well-known, serotonin-reuptake inhibitors (SRIs) are unsuccessful in management of forty to sixty percent of patients suffering from obsessivecompulsive disorder (OCD). So, purpose of the present trial was to assess that whether addon aripiprazole, as adjunctive to SRIs, is helpful in cases with treatment-resistant OCD.
Method: In an Open-prospective, single-arm interventional study with blinded rating, sixteen patients with OCD, who had not improved noticeably by serotonin-reuptake inhibitors, after maximum dosage and period, were allocated to get aripiprazole plus their SRIs for eight weeks. Management outcome was measured by means of the Yale-Brown Obsessive Compulsive Scale (YBOCS). Complete reaction to the abovementioned augmentative therapy was demarcated of at least fifty percent reduction in YBOCS’ score and partial reaction as equivalent to or >25% - <50% reduction in YBOCS in comparison with the starting point.
Results: Neither of patients responded with at least 25% decrease in YBOCS score to the aripiprazole addition (20 mg/day). 18% of cases experienced a reduction between 10-20%, and 68% of them less than 10%. Two patients did not show any change at all. The mean+/-SD baseline YBOCS’ score of 35.2 +/- 2.9 dropped to a mean of 32.8 +/- 4.1 at endpoint with a mean reduction of 8.8+/- 7.8% (p<0.06).
Conclusion: Within the limits of statistical power, this assessment does not offer additional proof that adding of aripiprazole to current SRI treatment could be worthwhile for cases suffering from treatment-resistant OCD.
Export Options
About this article
Cite this article as:
Shoja Shafti Saeed, Aripiprazole Addition to Serotonin Reuptake Inhibitor in Treatment-Resistant Obsessive-Compulsive Disorder, Current Psychopharmacology 2014; 3 (3) . https://dx.doi.org/10.2174/221155600303150629162749
DOI https://dx.doi.org/10.2174/221155600303150629162749 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Development of Polymeric Prodrugs as a Therapeutic Agent for Alzheimers Disease by Mechanochemical Solid-State Polymerization
Current Medicinal Chemistry - Central Nervous System Agents Prediction of Human Drug Metabolizing Enzyme Induction
Current Drug Metabolism Formulation and Optimization of 5-Fluorouracil Loaded Chitosan Nanoparticles Employing Central Composite Design
Drug Delivery Letters Lobar Atrophy in Frontotemporal Dementia: Diagnostic and Prognostic Implications
Current Alzheimer Research Potential Chemopreventive Role of Boldine Against Hepatocellular Carcinoma via Modulation of Cell Cycle Proteins in Rat Model
Anti-Cancer Agents in Medicinal Chemistry Cognitive Impairment and Dementia in Patients with Parkinson Disease
Current Topics in Medicinal Chemistry Editorial: [Hot Topic: Keeping Track of an Expanding Subject - Recent Trends in Immunology and their Clinical Implications]
Current Pharmaceutical Design Nicotine and Tobacco Particulate Self-Administration: Effects of Mecamylamine, SCH23390 and Ketanserin Pretreatment
Current Psychopharmacology Enhancement of Delayed Audiovisual Response in Parkinson’s Disease: A Comparison with Normal Aged Controls
Neuroscience and Biomedical Engineering (Discontinued) The Boundary between Hypochondriasis, Personality Dysfunction, and Trauma
Current Psychiatry Reviews Chemical Modifications of Ketoprofen (NSAID) in Search of Better Lead Compounds: A Review of Literature From 2004-2016
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Tolerance Induction by Gene Transfer to Lymphocytes
Current Gene Therapy Methionine-Independent Translation Initiation from Naturally Occurring Non-AUG Codons
Current Chemical Biology Selective Androgen Receptor Modulators Antagonize Apolipoprotein E4-Induced Cognitive Impairments
Letters in Drug Design & Discovery Matter of Life and Death: the Pharmacological Approaches Targeting Apoptosis in Brain Diseases
Current Pharmaceutical Design Zinc in the Glutamatergic Theory of Depression
Current Neuropharmacology Advances in Human Cytochrome P450 and Personalized Medicine
Current Drug Metabolism Recent Approaches to Novel Anti-Alzheimer Therapy
Current Pharmaceutical Design Nonviral Approach for Targeted Nucleic Acid Delivery
Current Medicinal Chemistry Metabolism-based Drug-drug Interactions in Patients with Chronic Respiratory Diseases: A Review Focusing on Drugs Affecting the Respiratory System
Current Drug Metabolism